Clinical Trial

Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual acuity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-28; most recent amendment 2026-02-12.
Trial Details
NCT Number NCT07390253
Lead Sponsor Vienna Institute for Research in Ocular Surgery
Conditions Neovascular (Wet) Age-Related Macular Degeneration
Enrollment 50 participants
Start Date 2024-09-18
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-17